TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Being Patient founder Deborah Kan describes questions raised by her blood-test results and examines how cholesterol transport in the brain may relate to ApoE4 and Alzheimer’s risk. Researchers are testing whether a cholesterol-lowering approach could help people at risk, but no cholesterol drug has been shown to prevent Alzheimer’s or protect memory.
Being Patient founder Deborah Kan has published a personal report on how cholesterol transport in the brain may relate to ApoE4 and Alzheimer’s risk, while a company-sponsored trial tests a cholesterol-lowering approach in people at risk. The report describes the biological questions behind the research, but says no cholesterol drug has been shown to prevent Alzheimer’s or protect memory.
Kan says a blood test she took about a year before writing the report measured 130 biomarkers. Her overall cholesterol result was normal, she writes, while her HDL and LDL particle measurements were out of range. The report does not provide the actual particle values or say what they mean for her personal health; Kan frames them as a reason she wanted to understand the research.
The article distinguishes cholesterol made in the brain from cholesterol circulating in the blood. It says dietary cholesterol does not cross the blood-brain barrier, and that the brain makes its own cholesterol. Blood cholesterol may still affect brain health through blood vessels: neurologist Dr. Gregory Jicha told Being Patient that high LDL can contribute to vessel buildup and impede the delivery of oxygen and nutrients to the brain.
Inside the brain, astrocytes produce cholesterol and transport it to neurons in packages involving the ApoE protein, the report says. Endocrinologist Dr. Heather Ferris told Being Patient that this transport process may connect to the production of amyloid, a protein that can accumulate in Alzheimer’s plaques. People with ApoE4 carry a version of ApoE associated with increased Alzheimer’s risk, but researchers have not settled exactly how it raises that risk.
Why ApoE4 Cholesterol Research Matters
The research matters because it asks whether a specific biological process—how cholesterol is moved and cleared in the brain—could help explain some of the increased Alzheimer’s risk associated with ApoE4. If researchers can establish a causal role and safely influence that process, it could point toward a treatment target. At present, that is a research possibility, not a demonstrated benefit for patients.
The distinction between blood cholesterol and brain cholesterol also matters for readers interpreting routine blood tests. Kan’s report does not establish that her particle results indicate a brain problem, nor that changing a blood cholesterol measure would alter Alzheimer’s risk. Personal test results and population-level research findings are not interchangeable; people should discuss individual results with a qualified health professional.
The report also raises a practical question about statins, medicines commonly used to lower blood cholesterol. It says existing trials have not convincingly answered whether statins provide long-term brain benefits. That uncertainty does not show that statins are ineffective for their established uses, and the article does not advise readers to start, stop or change medication.
Products Worth Considering
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Withings BPM Connect Smart Blood Pressure Monitor
Fitbit Sense 2 Advanced Health and Fitness Smartwatch, Blue Mist/Pale Gold
As an affiliate, we earn on qualifying purchases.
How Cholesterol Transport Enters the Story
Cholesterol is a component of cell membranes, including those around nerve cells. In the account Kan gives of Jicha’s explanation, those membranes need to maintain both structure and flexibility as nerve cells function and form connections. The brain’s cholesterol supply is managed locally rather than taken directly from food, according to the report.
That local system relies partly on astrocytes, brain cells that produce cholesterol and distribute it to neurons. ApoE acts as a carrier in that process. The report presents one proposed connection to Alzheimer’s: ApoE transports cholesterol to nerve-cell surfaces, where related processes may contribute to amyloid generation. It does not claim that this pathway alone causes Alzheimer’s.
ApoE4 is one form of the ApoE protein and is linked to higher Alzheimer’s risk. Kan quotes Jicha saying that ApoE versions that do not move cholesterol properly are associated with a large increase in risk. Ferris, however, stresses that the explanation remains unsettled: researchers have studied ApoE4 for many years, but controversy persists over the precise mechanisms.
“I call astrocytes the liver of the brain.”
— Dr. Heather Ferris, endocrinologist at the University of Virginia, speaking to Being Patient
What the Research Has Not Established
The precise way ApoE4 raises Alzheimer’s risk remains disputed, according to the experts quoted in the report. The article describes cholesterol transport and amyloid generation as areas of investigation, not a settled account of the disease’s cause.
It is also unknown whether lowering cholesterol through medication can prevent Alzheimer’s or preserve memory. The report says trials so far have not convincingly established long-term brain benefits from statins. It gives no results from the NewAmsterdam Pharma trial, and does not specify its enrollment, treatment details, outcome measures or completion date.
Kan’s personal blood-test results are not reported in enough detail to interpret them, and the article does not connect those measurements to a diagnosis or an individual estimate of Alzheimer’s risk. A result for cholesterol particles should not be treated as evidence of Alzheimer’s or as proof that a particular intervention will help.
Trial Results and Research Questions
NewAmsterdam Pharma is running a trial to test whether its cholesterol-lowering approach could help prevent Alzheimer’s in people at risk. The company’s theory, as described by Being Patient, is that ApoE4 may be less effective at clearing cholesterol. The source does not report trial results or a schedule for when they are expected.
Kan also said she planned to discuss the topic with Dr. Cheryl Wellington, a University of British Columbia professor and brain-health researcher whose work includes cholesterol metabolism, inflammation and dementia risk. The scheduled conversation was intended to address whether changing brain cholesterol transport could be a realistic path to treatment and what the research means for ApoE4 carriers.
The next meaningful evidence will come from research that tests whether the proposed mechanism is correct and whether an intervention changes clinical outcomes—not simply cholesterol measurements. Until such results are available, the relationship remains an active research question, and no cholesterol medicine can be described on the basis of this report as an established Alzheimer’s-prevention treatment.
Key Questions
Does cholesterol in food directly enter the brain?
The Being Patient report says dietary cholesterol does not cross the blood-brain barrier; the brain makes its own cholesterol. Blood cholesterol may affect the brain indirectly through its effects on blood vessels.
What is ApoE4?
ApoE4 is a version of the ApoE protein, which helps transport cholesterol in the brain. It is associated with increased Alzheimer’s risk, but researchers have not fully established how it contributes to that risk.
Have statins been shown to prevent Alzheimer’s?
The report says trials have not convincingly answered whether statins provide long-term brain benefits. It does not establish that statins prevent Alzheimer’s or protect memory. Medication decisions should be discussed with a qualified health professional.
Is a cholesterol-lowering drug being tested for Alzheimer’s prevention?
Yes. NewAmsterdam Pharma is running a trial of a cholesterol-lowering approach in people at risk, based on a theory about ApoE4 and cholesterol clearance. The source provides no trial results or expected completion date.
Do out-of-range cholesterol particle results mean someone has Alzheimer’s?
No such conclusion is supported by the report. Kan does not provide her particle values or link them to a diagnosis. Anyone with questions about personal test results should discuss them with a qualified health professional.
Source: beingpatient.com
